Hikari Tsushin Inc. grew its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 22.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 285,554 shares of the company’s stock after buying an additional 51,937 shares during the quarter. Zoetis comprises 1.3% of Hikari Tsushin Inc.’s investment portfolio, making the stock its 11th biggest holding. Hikari Tsushin Inc. owned 0.07% of Zoetis worth $19,940,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in ZTS. TIAA CREF Individual & Institutional Services LLC bought a new position in Zoetis in the 3rd quarter worth approximately $263,000. Whittier Trust Co. lifted its holdings in shares of Zoetis by 2.1% during the third quarter. Whittier Trust Co. now owns 12,073 shares of the company’s stock worth $903,000 after buying an additional 249 shares during the last quarter. Advisors Asset Management Inc. bought a new stake in shares of Zoetis in the third quarter valued at approximately $6,125,000. Edmond DE Rothschild Holding S.A. boosted its position in shares of Zoetis by 8.6% in the third quarter. Edmond DE Rothschild Holding S.A. now owns 604,408 shares of the company’s stock valued at $42,206,000 after acquiring an additional 47,883 shares during the period. Finally, Minot DeBlois Advisors LLC boosted its position in shares of Zoetis by 3.0% in the third quarter. Minot DeBlois Advisors LLC now owns 5,353 shares of the company’s stock valued at $374,000 after acquiring an additional 155 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.
Recent Zoetis Headlines
Here are a few of the latest headlines about ZTS:
- Positive Sentiment: The USDA licensed Zoetis’s Poulvac® Procerta® HVT-ND-ILT, a vaccine for chickens targeting three diseases. The approval expands the company’s poultry-health portfolio and could create a commercial opportunity, though the headlines provide no sales or earnings estimates. Article: Zoetis Receives USDA License for Poulvac Procerta HVT-ND-ILT Vaccine for Chickens
- Positive Sentiment: Recent coverage also highlighted news about a dog-allergy treatment and described Zoetis shares as potentially inexpensive. The headline does not provide enough detail to assess the treatment’s likely financial impact. Article: Zoetis Stock Still Looks Cheap Following Fresh Dog Allergy Treatment News
- Neutral Sentiment: Brokerages’ consensus target price is reported at $101.25, while Barclays maintained a Hold rating—signals of potential upside in analyst estimates but also a cautious view from at least one firm. Article: Zoetis Stock Has Consensus Target Price of $101.25 According to Brokerages Article: Barclays Remains a Hold on Zoetis
Zoetis Stock Performance
Shares of NYSE:ZTS opened at $79.09 on Friday. The business’s fifty day moving average price is $77.16 and its two-hundred day moving average price is $90.55. Zoetis Inc. has a fifty-two week low of $68.77 and a fifty-two week high of $132.49. The stock has a market capitalization of $32.14 billion, a price-to-earnings ratio of 13.45, a price-to-earnings-growth ratio of 1.22 and a beta of 0.67. The company has a debt-to-equity ratio of 2.51, a current ratio of 2.35 and a quick ratio of 1.40.
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.51 by $0.24. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period last year, the business earned $1.70 earnings per share. The business’s revenue was down 1.3% on a year-over-year basis. As a group, analysts predict that Zoetis Inc. will post 6.29 EPS for the current fiscal year.
Zoetis Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be given a $0.53 dividend. The ex-dividend date is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s payout ratio is 36.05%.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the stock. Citigroup dropped their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Jefferies Financial Group increased their price target on shares of Zoetis from $83.00 to $85.00 in a report on Friday, November 6th. BTIG Research dropped coverage on shares of Zoetis in a research report on Friday, October 30th. They issued a “buy” rating and a $200.00 price target on the stock. William Blair lowered shares of Zoetis from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 6th. Finally, Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a report on Tuesday, August 25th. Eight equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average target price of $101.25.
Read Our Latest Analysis on Zoetis
Zoetis Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Stories
- Five stocks we like better than Zoetis
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
